Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C)
Brief Summary: The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months.

Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits.

The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial.

The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.


Options:
A: Arm Label: Peginterferon Alfa-2a + Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Peginterferon alfa-2a [Pegasys] | Arm Label: Peginterferon Alfa-2b + Ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peginterferon alfa-2b (PEG-Intron), Drug: Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Peginterferon Alfa-2a + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2b (PEG-Intron); Assigned to Arm(s): Peginterferon Alfa-2b + Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Peginterferon Alfa-2b + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a [Pegasys]; Assigned to Arm(s): Peginterferon Alfa-2a + Ribavirin
B: Arm Label: PegIntron 1.5 ug/kg/wk plus REBETOL; Type: EXPERIMENTAL; Interventions: Biological: PegIntron (peginterferon alfa-2b; SCH 54031), Drug: REBETOL (ribavirin; SCH 18908) | Arm Label: PegIntron 1.0 ug/kg/wk plus REBETOL; Type: EXPERIMENTAL; Interventions: Biological: PegIntron (peginterferon alfa-2b; SCH 54031), Drug: REBETOL (ribavirin; SCH 18908) | Arm Label: PEGASYS 180 ug/wk Plus COPEGUS; Type: ACTIVE_COMPARATOR; Interventions: Biological: PEGASYS (peginterferon alfa-2a), Drug: COPEGUS (ribavirin) | Intervention Type: BIOLOGICAL; Name: PegIntron (peginterferon alfa-2b; SCH 54031); Assigned to Arm(s): PegIntron 1.5 ug/kg/wk plus REBETOL | Intervention Type: BIOLOGICAL; Name: PegIntron (peginterferon alfa-2b; SCH 54031); Assigned to Arm(s): PegIntron 1.0 ug/kg/wk plus REBETOL | Intervention Type: DRUG; Name: REBETOL (ribavirin; SCH 18908); Assigned to Arm(s): PegIntron 1.0 ug/kg/wk plus REBETOL, PegIntron 1.5 ug/kg/wk plus REBETOL | Intervention Type: BIOLOGICAL; Name: PEGASYS (peginterferon alfa-2a); Assigned to Arm(s): PEGASYS 180 ug/wk Plus COPEGUS | Intervention Type: DRUG; Name: COPEGUS (ribavirin); Assigned to Arm(s): PEGASYS 180 ug/wk Plus COPEGUS
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Peginterferon alfa-2a + Ribavirin, Drug: Peginterferon alfa-2a | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Peginterferon alfa-2a + Ribavirin | Intervention Type: DRUG; Name: Peginterferon alfa-2a + Ribavirin; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Peginterferon alfa-2a; Assigned to Arm(s): 1
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated interferon alpha 2a, Drug: Ribavirin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated interferon alpha 2 b plus ribavirin | Intervention Type: DRUG; Name: Pegylated interferon alpha 2a; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Pegylated interferon alpha 2 b plus ribavirin; Assigned to Arm(s): 2

Answer: C